

**Amendments to the Claims:**

This claim listing will replace all prior versions and listings of claims in the application:

**Claim Listing:**

1. (Previously Amended) A synthetic oligonucleotide selected from the group consisting of SEQ ID NOS:7-19 and 45, which oligonucleotide inhibits HBV replication.
- 2-7 (Canceled)
8. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 7 or 58.
9. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 8 or 59.
10. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 9, 60, or 61.
11. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 10.
12. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 11.
13. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 12.
14. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 13.
15. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 14.
16. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 15, 62, or 63.
17. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 16 or 64.
18. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 17.

19. (Original) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 18.
20. (Currently Amended) The synthetic oligonucleotide of claim 1 having SEQ ID NO: 19 or 65.
- 21-35 (Canceled)
36. (Previously Amended) The synthetic oligonucleotide of claim 1, wherein the oligonucleotide is SEQ ID NO:45.
- 37-39 (Canceled)
40. (Original) The synthetic oligonucleotide of claim 1 which is modified.
41. (Original) The oligonucleotide of claim 40 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
42. (Original) The oligonucleotide of claim 41 comprising at least one phosphorothioate internucleotide linkage.
43. (Original) The oligonucleotide of claim 42 comprising one phosphorothioate internucleotide linkage.
44. (Original) The oligonucleotide of claim 1 which comprises at least one deoxyribonucleotide.
45. (Original) The oligonucleotide of claim 1 which comprises at least one ribonucleotide.
46. (Original) The oligonucleotide of claim 44 which comprises at least one ribonucleotide.
47. (Original) The oligonucleotide of claim 45 comprising at least one 2'-O-methyl nucleotide.

48. (Original) A kit comprising at least one oligonucleotide of claim 1.
49. (Original) A kit comprising at least two oligonucleotides of claim 1.
50. (Previously Amended) A composition comprising at least one oligonucleotide of claim 1 admixed with a pharmaceutically acceptable carrier.
- 51-206 (Canceled)
207. (Previously Added) The synthetic oligonucleotide of claim 16 which is modified.
208. (Previously Added) The oligonucleotide of claim 207 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
209. (Previously Added) The oligonucleotide of claim 208 comprising at least one phosphorothioate internucleotide linkage.
210. (Previously Added) The oligonucleotide of claim 209 comprising one phosphorothioate internucleotide linkage.
211. (Previously Added) The oligonucleotide of claim 17 which comprises at least one deoxyribonucleotide.
212. (Previously Added) The oligonucleotide of claim 17 which comprises at least one ribonucleotide.
213. (Previously Added) The oligonucleotide of claim 211 which comprises at least one ribonucleotide.
214. (Previously Added) The oligonucleotide of claim 212 comprising at least one 2'-O-methyl nucleotide.
215. (Previously Added) A kit comprising at least the oligonucleotide of claim 16.

216. (Previously Added) The synthetic oligonucleotide of claim 19 which is modified.
217. (Previously Added) The oligonucleotide of claim 216 wherein the modification comprises at least one internucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
218. (Previously Added) The oligonucleotide of claim 217 comprising at least one phosphorothioate internucleotide linkage.
219. (Previously Added) The oligonucleotide of claim 216 comprising phosphorothioate internucleotide linkages.
220. (Previously Added) The oligonucleotide of claim 219 which comprises at least one deoxyribonucleotide.
221. (Previously Added) The oligonucleotide of claim 220 which comprises at least one ribonucleotide.
222. (Previously Added) The oligonucleotide of claim 19 which comprises at least one ribonucleotide.